Clinical Trial

A Study of Peptide Receptor Radionuclide Therapy (PRRT) Use in Neuroendocrine Tumor (NET) Patients in Germany

Name: A Study of Peptide Receptor Radionuclide Therapy (PRRT) Use in Neuroendocrine Tumor (NET) Patients in Germany — clinical trial record (NCT07653126)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: LUNET-2

Completed

View on ClinicalTrials.gov →

Summary

The aim of this study was to assess patient characteristics and treatment patterns of gastro-enteropancreatic neuroendocrine tumor (GEP-NET) patients who received PRRT in German routine care.

Trial Details

NCT Number	NCT07653126
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Gastro-enteropancreatic Neuroendocrine Tumor
Enrollment	117 participants
Start Date	2023-04-03
Primary Completion	2023-09-29 (estimated)
Study Completion	2023-09-29 (estimated)
Updated on ClinicalTrials.gov	2026-06-17